Prediction of disease-free survival of N1/2 non-small cell lung cancer after adjuvant chemotherapy by the biomarker RPMB

No molecular biomarkers have been proven applicable in clinical practice to identify patients who can benefit from adjuvant chemotherapy in non-small cell lung cancer (NSCLC). In this study, we established a biomarker, RPMB, short for promotor methylation burden of DNA repair genes (DRGs), to identi...

Descripción completa

Detalles Bibliográficos
Autores principales: An, Ning, Yang, Xue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10368914/
https://www.ncbi.nlm.nih.gov/pubmed/37501955
http://dx.doi.org/10.1016/j.heliyon.2023.e18266

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10368914/
https://www.ncbi.nlm.nih.gov/pubmed/37501955
http://dx.doi.org/10.1016/j.heliyon.2023.e18266

Ejemplares similares